Abstract
Background: Substance use disorders (SUDs) are a considerable public health problem. Attention-deficit/hyperactivity disorder (ADHD) frequently occurs in patients with SUD. Several studies demonstrated that ADHD constitutes a significant risk factor for the development of SUDs and suggest that childhood ADHD pharmacotherapy might help prevent development of SUD. Objectives: The study aimed to explore the effect of childhood ADHD pharmacotherapy on later life’s functional impairment and substance use patterns. Methods: Treatment-seeking SUD patients with ADHD (n = 52) were recruited from various rehabilitation facilities in South Africa. Adult ADHD individuals without SUD (n = 48) were recruited from clinicians, retail pharmacies, and the general public. SUD participants in rehabilitation facilities were screened for and diagnosed with ADHD. Lifetime substance use was assessed using self-report. ADHD-related functional impairment was assessed by the Weiss Functional Impairment Rating Scale (WFIRS). Information on present and lifetime use of ADHD medication was obtained. Clinical outcomes between those with and without a history of ADHD pharmacotherapy were compared. Results: Medicated participants (n = 59) showed lower levels of ADHD-related impairment across all functional domains (p < 0.001), compared to non-medicated participants (n = 41). They also consumed less alcohol (p = 0.04), cannabis (p < 0.001), and illicit drugs (p = 0.006) compared to the non-medicated group. Furthermore, medicated participants had a lower frequency of tobacco use compared to non-medicated participants (p = 0.04). ADHD patients without SUD also more often received medication (100% vs. 18.6%; p < 0.001) and for a longer time (121.10 vs. 9.52 months; p < 0.001). Conclusion: Childhood ADHD pharmacotherapy might be associated with a decreased risk for substance use in adulthood and lower ADHD-related impairment. Despite study limitations, these findings underline the importance of early ADHD detection and treatment, which might prevent SUD.
References
1.
Faraone
SV
, Banaschewski
T
, Coghill
D
, Zheng
Y
, Biederman
J
, Bellgrove
MA
, . The world federation of ADHD international consensus statement: 208 evidence-based conclusions about the disorder
. Neurosci Biobehav Rev
. 2021
;128
:789
–818
.2.
American Psychiatric Association
. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®)
. 5th ed. Arlington, VA
: American Psychiatric Publishing
; 2013
.3.
Polanczyk
G
, De Lima
MS
, Horta
BL
, Biederman
J
, Rohde
LA
. The worldwide prevalence of ADHD: A systematic review and metaregression analysis
. Am J Psychiatry
. 2007
;164
(6
):942
–8
.4.
Willcutt
EG
. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review
. Neurotherapeutics
. 2012
;9
(3
):490
–9
.5.
Xu
G
, Strathearn
L
, Liu
B
, Yang
B
, Bao
W
. Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016
. JAMA Netw Open
. 2018
;1
(4
):e181471
.6.
Lara
C
, Fayyad
J
, De Graaf
R
, Kessler
RC
, Aguilar-Gaxiola
S
, Angermeyer
M
, . Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative
. Biol Psychiatry
. 2009
;65
(1
):46
–54
.7.
DuPaul
GJ
, Weyandt
LL
, O'Dell
SM
, Varejao
M
. College students with ADHD: Current status and future directions
. J Atten Disord
. 2009
;13
(3
):234
–50
.8.
Faraone
SV
, Biederman
J
, Mick
E
. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies
. Psychol Med
. 2006
;36
(2
):159
–65
.9.
Barkley
RA
, Fischer
M
, Smallish
L
, Fletcher
K
. Young adult outcome of hyperactive children: adaptive functioning in major life activities
. J Am Acad Child Adolesc Psychiatry
. 2006
;45
(2
):192
–202
.10.
Adler
LA
, Faraone
SV
, Spencer
TJ
, Berglund
P
, Alperin
S
, Kessler
RC
. The structure of adult ADHD
. Int J Methods Psychiatr Res
. 2017
;26
(1
):e1555
.11.
Wender
PH
, Wolf
LE
, Wasserstein
J
. Adults with ADHD. An overview.
. Ann N Y Acad Sci
. 2001
;931
(1
):1
–16
.12.
Elkins
IJ
, McGue
M
, Iacono
WG
. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse
. Arch Gen Psychiatry
. 2007
;64
(10
):1145
–52
.13.
Mannuzza
S
, Klein
RG
, Bessler
A
, Malloy
P
, Hynes
ME
. Educational and occupational outcome of hyperactive boys grown up
. J Am Acad Child Adolesc Psychiatry
. 1997
;36
(9
):1222
–7
.14.
Eakin
L
, Minde
K
, Hechtman
L
, Ochs
E
, Krane
E
, Bouffard
R
, . The marital and family functioning of adults with ADHD and their spouses
. J Atten Disord
. 2004
;8
(1
):1
–10
.15.
Weafer
J
, Milich
R
, Fillmore
MT
. Behavioral components of impulsivity predict alcohol consumption in adults with ADHD and healthy controls
. Drug Alcohol Depend
. 2011
;113
(2–3
):139
–46
.16.
Crunelle
C
, Matthys
F
. Cocaine dependence and attention deficit hyperactivity disorder
. The neuroscience of cocaine
. London
: Elsevier
; 2017
. p. 383
–93
.17.
Biederman
J
, Wilens
TE
, Mick
E
, Faraone
SV
, Spencer
T
. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence
. Biol Psychiatry
. 1998
;44
(4
):269
–73
.18.
Charach
A
, Yeung
E
, Climans
T
, Lillie
E
. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses
. J Am Acad Child Adolesc Psychiatry
. 2011
;50
(1
):9
–21
.19.
Groenman
AP
, Janssen
TWP
, Oosterlaan
J
. Childhood psychiatric disorders as risk factor for subsequent substance abuse: a meta-analysis
. J Am Acad Child Adolesc Psychiatry
. 2017
;56
(7
):556
–69
.20.
Szobot
CM
, Rohde
LA
, Bukstein
O
, Molina
BSG
, Martins
C
, Ruaro
P
, . Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case–control study
. Addiction
. 2007
;102
(7
):1122
–30
.21.
van Emmerik-van Oortmerssen
K
, van de Glind
G
, van den Brink
W
, Smit
F
, Crunelle
CL
, Swets
M
, . Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis
. Drug Alcohol Depend
. 2012
;122
(1–2
):11
–9
.22.
Wilens
TE
, Morrison
NR
. The intersection of attention-deficit/hyperactivity disorder and substance abuse
. Curr Opin Psychiatry
. 2011
;24
(4
):280
–5
.23.
Schellekens
AFA
, van den Brink
W
, Kiefer
F
, Goudriaan
AE
. Often overlooked and ignored, but do not underestimate its relevance: ADHD in addiction–addiction in ADHD
. Eur Addict Res
. 2020
;26
(4–5
):169
–72
.24.
Khantzian
EJ
. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications
. Har Rev of Psychiatry
. 1997
;4
(5
):231
–44
.25.
Wilens
TE
. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues
. Psychiatri Clin
. 2004
;27
(2
):283
–301
.26.
Kessler
RC
, Adler
L
, Barkley
R
, Biederman
J
, Conners
CK
, Demler
O
, . The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication
. Am J Psychiatry
. 2006
;163
(4
):716
–23
.27.
Crunelle
CL
, van den Brink
W
, Moggi
F
, Konstenius
M
, Franck
J
, Levin
FR
, . International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder
. Eur Addict Res
. 2018
;24
(1
):43
–51
.28.
Özgen
H
, Spijkerman
R
, Noack
M
, Holtmann
M
, Schellekens
ASA
, Van De Glind
G
, . International consensus statement for the screening, diagnosis, and treatment of adolescents with concurrent attention-deficit/hyperactivity disorder and substance use disorder
. Eur Addict Res
. 2020
;26
(4–5
):223
–32
.29.
Barkley
RA
, Murphy
KR
. Impairment in occupational functioning and adult ADHD: the predictive utility of executive function (EF) ratings versus EF tests
. Arch Clin Neuropsychol
. 2010
;25
(3
):157
–73
.30.
Biederman
J
, Faraone
SV
, Spencer
TJ
, Mick
E
, Monuteaux
MC
, Aleardi
M
. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community
. J Clin Psychiatry
. 2006
;67
(4
):524
–40
.31.
Ginsberg
Y
, Quintero
J
, Anand
E
, Casillas
M
, Upadhyaya
HP
. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: a review of the literature
. Prim Care Companion CNS Disord
. 2014
;16
(3
):PCC.13r01600
.32.
Weiss
MD
, McBride
NM
, Craig
S
, Jensen
P
. Conceptual review of measuring functional impairment: findings from the Weiss functional impairment rating scale
. Evid Based Ment Health
. 2018
;21
(4
):155
–64
.33.
Biederman
J
, Monuteaux
MC
, Spencer
T
, Wilens
TE
, Faraone
SV
. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study
. Pediatrics
. 2009
;124
(1
):71
–8
.34.
Groenman
AP
, Schweren
LJS
, Weeda
W
, Luman
M
, Noordermeer
SDS
, Heslenfeld
DJ
, . Stimulant treatment profiles predicting co-occurring substance use disorders in individuals with attention-deficit/hyperactivity disorder
. Eur Child Adolesc Psychiatry
. 2019
;28
(9
):1213
–22
.35.
Wilens
TE
, Adamson
J
, Monuteaux
MC
, Faraone
SV
, Schillinger
M
, Westerberg
D
, . Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents
. Arch Pediatr Adolesc Med
. 2008
;162
(10
):916
–21
.36.
Heatherton
TF
, Kozlowski
LT
, Frecker
RC
, Fagerstrom
KO
. The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire
. Br J Addict
. 1991
;86
(9
):1119
–27
.37.
Pomerleau
OF
, Downey
KK
, Stelson
FW
, Pomerleau
CS
. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder
. J Subst Abuse
. 1995
;7
(3
):373
–8
.38.
Vink
JM
, Willemsen
G
, Beem
AL
, Boomsma
DI
. The Fagerström Test for Nicotine Dependence in a Dutch sample of daily smokers and ex-smokers
. Addict Behav
. 2005
;30
(3
):575
–9
.39.
Kessler
RC
, Adler
L
, Ames
M
, Demler
O
, Faraone
S
, Hiripi
E
, . The World Health Organization adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population
. Psychol Med
. 2005
;35
(2
):245
–56
.40.
Fayyad
J
, De Graaf
R
, Kessler
R
, Alonso
J
, Angermeyer
M
, Demyttenaere
K
, . Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
. Br J Psychiatry
. 2007
;190
(5
):402
–9
.41.
Takeda
T
, Tsuji
Y
, Kurita
H
. Psychometric properties of the Japanese version of the Adult Attention-deficit hyperactivity disorder (ADHD) Self-Report Scale (ASRS-J) and its short scale in accordance with DSM-5 diagnostic criteria
. Res Dev Disabil
. 2017
;63
:59
–66
.42.
Yeh
CB
, Gau
SSF
, Kessler
RC
, Wu
YY
. Psychometric properties of the Chinese version of the adult ADHD self-report Scale
. Int J Methods Psychiatr Res
. 2008
;17
(1
):45
–54
.43.
Van de Glind
G
, van den Brink
W
, Koeter
MWJ
, Carpentier
P-J
, van Emmerik-van Oortmerssen
K
, Kaye
S
, . Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients
. Drug Alcohol Depend
. 2013
;132
(3
):587
–96
.44.
Kooij
J
, Francken
M
. DIVA 2.0
. Diagnostic interview Voor ADHD in adults bij volwassenen [DIVA 2 0 diagnostic interview ADHD in adults]
. The Netherlands
: DIVA Foundation
; 2010
. http://www.divacenter.eu/DIVA.aspx.45.
Fadeuilhe Grau
C
, Palma-Álvarez
R
, Nasillo
V
, Palomar
G
, Corrales
M
, Richarte
V
, . Criteria and concurrent validity of DIVA 2.0: a semi-structured diagnostic interview for adult ADHD
. Eur Psychiatry
. 2016
;33
(S1
):S630
–S
.46.
Ramos-Quiroga
JA
, Nasillo
V
, Richarte
V
, Corrales
M
, Palma
F
, Ibáñez
P
, . Criteria and concurrent validity of DIVA 2.0: a semi-structured diagnostic interview for adult ADHD
. J Atten Disord
. 2019
;23
(10
):1126
–35
.47.
Canu
WH
, Hartung
CM
, Stevens
AE
, Lefler
EK
. Psychometric properties of the Weiss Functional Impairment Rating Scale: Evidence for utility in research, assessment, and treatment of ADHD in emerging adults
. J Atten Disord
. 2020
;24
(12
):1648
–60
.48.
Thompson
T
, Lloyd
A
, Joseph
A
, Weiss
M
. The Weiss functional impairment rating scale-parent form for assessing ADHD: evaluating diagnostic accuracy and determining optimal thresholds using ROC analysis
. Qual Life Res
. 2017
;26
(7
):1879
–85
.49.
Castells
X
, Ramos-Quiroga
JA
, Rigau
D
, Bosch
R
, Nogueira
M
, Vidal
X
, . Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis
. CNS drugs
. 2011
;25
(2
):157
–69
.50.
Koesters
M
, Becker
T
, Kilian
R
, Fegert
JM
, Weinmann
S
. Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder
. J Psychopharmacol
. 2009
;23
(7
):733
–44
.51.
Fredriksen
M
, Halmøy
A
, Faraone
SV
, Haavik
J
. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies
. Eur Neuropsychopharmacol
. 2013
;23
(6
):508
–27
.52.
Carpentier
P-J
, Levin
FR
. Pharmacological treatment of ADHD in addicted patients: what does the literature tell us
. Harv Rev Psychiatry
. 2017
;25
(2
):50
–64
.53.
Kooij
JJS
, Bijlenga
D
, Salerno
L
, Jaeschke
R
, Bitter
I
, Balázs
J
, . Updated European consensus statement on diagnosis and treatment of adult ADHD
. Eur Psychiatry
. 2019
;56
:14
–34
.54.
Gudjonsson
GH
, Sigurdsson
JF
, Sigfusdottir
ID
, Young
S
. An epidemiological study of ADHD symptoms among young persons and the relationship with cigarette smoking, alcohol consumption and illicit drug use
. J Child Psychol Psychiatry
. 2012
;53
(3
):304
–12
.55.
Kaye
S
, Darke
S
, Torok
M
. Attention deficit hyperactivity disorder (ADHD) among illicit psychostimulant users: a hidden disorder
. Addiction
. 2013
;108
(5
):923
–31
.56.
Coetzee
C
, Truter
I
, Meyer
A
. Prevalence and characteristics of South African treatment-seeking patients with substance use disorder and co-occurring attention-deficit/hyperactivity disorder
. Expert Rev Clin Pharmacol
. 2020
;13
(11
):1271
–80
.57.
Wilens
TE
, Adamson
J
, Sgambati
S
, Whitley
J
, Santry
A
, Monuteaux
MC
, . Do individuals with ADHD self‐medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD
. Am J Addict
. 2007
;16
(Suppl 1
):14
–21
; quiz 22–3. https://doi.org/10.1080/10550490601082742.58.
Wise
RA
. Roles for nigrostriatal: not just mesocorticolimbic – dopamine in reward and addiction
. Trends Neurosci
. 2009
;32
(10
):517
–24
.59.
Paraskevopoulou
M
, van Rooij
D
, Batalla
A
, Chauvin
R
, Luijten
M
, Schene
AH
, . Effects of substance misuse on reward-processing in patients with attention-deficit/hyperactivity disorder
. Neuropsychopharmacology
. 2021
;46
(3
):622
–31
.60.
Volkow
ND
, Fowler
JS
, Wang
GJ
, Baler
R
, Telang
F
. Imaging dopamine's role in drug abuse and addiction
. Neuropharmacology
. 2009
;56
(Suppl 1
):3
–8
.61.
Roncero
C
, Ortega
L
, Pérez-Pazos
J
, Lligoña
A
, Abad
AC
, Gual
A
, . Psychiatric comorbidity in treatment-seeking alcohol dependence patients with and without ADHD
. J Atten Disord
. 2019
;23
(12
):1497
–504
.62.
Biederman
J
, Monuteaux
MC
, Spencer
T
, Wilens
TE
, MacPherson
HA
, Faraone
SV
. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study
. Am J Psychiatry
. 2008
;165
(5
):597
–603
.63.
Hammerness
P
, Petty
C
, Faraone
SV
, Biederman
J
. Do stimulants reduce the risk for alcohol and substance use in youth with ADHD? A secondary analysis of a prospective, 24-month open-label study of osmotic-release methylphenidate
. J Atten Disord
. 2017
;21
(1
):71
–7
.64.
Benjamin
J
, Li
L
, Patterson
C
, Greenberg
BD
, Murphy
DL
, Hamer
DH
. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking
. Nat Genet
. 1996
;12
(1
):81
–4
.65.
Ebstein
RP
, Belmaker
RH
. Saga of an adventure gene: novelty Seeking, substance abuse and the dopamine D4 receptor (D4DR) exon III repeat polymorphism
. Mol Psychiatry
. 1997
;2
(5
):381
–4
.66.
Swanson
JM
, Flodman
P
, Kennedy
J
, Spence
MA
, Moyzis
R
, Schuck
S
, . Dopamine genes and ADHD
. Neurosci Biobehav Rev
. 2000
;24
(1
):21
–5
.67.
Faraone
SV
, Doyle
AE
, Mick
E
, Biederman
J
. Meta-analysis of the association between the 7-repeat allele of the dopamine D4 receptor gene and attention deficit hyperactivity disorder
. Am J Psychiatry
. 2001
;158
(7
):1052
–7
.68.
Guelke
L
. Freehold farmers and frontier settlers, 1657-1780
: The shaping of South African society
; 1989
. p. 1652
–840
.69.
70.
Dunne
EM
, Hearn
LE
, Rose
JJ
, Latimer
WW
. ADHD as a risk factor for early onset and heightened adult problem severity of illicit substance use: an accelerated gateway model
. Addict Behav
. 2014
;39
(12
):1755
–8
.71.
Asherson
P
, Akehurst
R
, Kooij
JJS
, Huss
M
, Beusterien
K
, Sasané
R
, . Under diagnosis of adult ADHD: cultural influences and societal burden
. J Atten Disord
. 2012
;16
(5 Suppl l
):20S
–38S
.72.
Dalsgaard
S
, Mortensen
PB
, Frydenberg
M
, Thomsen
PH
. ADHD, stimulant treatment in childhood and subsequent substance abuse in adulthood: a naturalistic long-term follow-up study
. Addict Behav
. 2014
;39
(1
):325
–8
.73.
Icick
R
, Moggi
F
, Slobodin
O
, Dom
G
, Mathys
F
, van den Brink
W
, . Attention deficit/hyperactivity disorder and global severity profiles in treatment-seeking patients with substance use disorders
. Eur Addict Res
. 2020
;26
(4–5
):201
–10
.74.
Sánchez-García
NC
, González
RA
, Ramos-Quiroga
JA
, van den Brink
W
, Luderer
M
, Blankers
M
, . Attention deficit hyperactivity disorder increases nicotine addiction severity in adults seeking treatment for substance use disorders: the role of personality disorders
. Eur Addict Res
. 2020
;26
(4–5
):191
–200
.75.
Ilbegi
S
, Groenman
AP
, Schellekens
A
, Hartman
CA
, Hoekstra
PJ
, Franke
B
, . Substance use and nicotine dependence in persistent, remittent, and late-onset ADHD: a 10-year longitudinal study from childhood to young adulthood
. J Neurodev Disord
. 2018
;10
(1
):42
.76.
World Medical Association
. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects
. Bull World Health Organ
. 2001
;79
(4
):373
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
